JB Capital LLC Invests $3.62 Million in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• JB Capital LLC invested approximately $3.62 million in Regeneron Pharmaceuticals, acquiring 6,904 shares during the second quarter.
• Regeneron reported a net margin of 31.37% and earnings of $12.89 per share for the last quarter, significantly exceeding analysts' expectations.
• Analysts remain optimistic, with a consensus rating of "Moderate Buy" and an average price target of $817.67 for Regeneron's stock.

JB Capital LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,904 shares of the biopharmaceutical company's stock, valued at approximately $3,624,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 31 shares in the last quarter. Activest Wealth Management lifted its stake in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 21 shares in the last quarter. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $27,000. Saudi Central Bank acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth about $27,000. Finally, Colonial Trust Advisors acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth about $32,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 1.1%

Shares of REGN stock opened at $569.90 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The stock has a market capitalization of $60.40 billion, a P/E ratio of 14.36, a price-to-earnings-growth ratio of 1.81 and a beta of 0.31. The company has a 50 day moving average price of $573.83 and a 200 day moving average price of $565.52. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,024.36.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $11.56 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on REGN shares. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Canaccord Genuity Group restated a "buy" rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research report on Monday, August 4th. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research report on Monday, August 4th. Finally, Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research report on Tuesday, September 2nd. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.